ITAT Mumbai deletes ₹433.14 crore royalty addition in Novartis case, ruling that trademark assignment need not include corporate identity, house marks or packaging.
Introduction
The Mumbai Bench of the Income Tax Appellate Tribunal (ITAT) has delivered an important ruling on the taxation of trademark transfers, holding that the sale of a registered trademark does not require the transfer of the seller’s entire corporate identity, house marks or product packaging. The Tribunal deleted an income tax addition of ₹433.14 crore that had been treated as royalty by the Income Tax Department in the case of Swiss pharmaceutical company Novartis AG.
The ruling clarifies the distinction between an outright transfer of intellectual property rights and the grant of permission to use a trademark. It also highlights the importance of examining contractual terms, ownership rights and the applicable Double Taxation Avoidance Agreement (DTAA) while determining the tax treatment of cross-border intellectual property transactions.
Case Details
- Case Name: Novartis AG v. Assistant Commissioner of Income Tax (International Taxation), Circle 3(3)(1)
- Tribunal: Income Tax Appellate Tribunal, Mumbai Bench
- Appeal Number: ITA No. 1027/Mum/2023
- Assessment Year: 2020–21
- Reported Citation: 2026 LLBiz ITAT (MUM) 296
- Key Issue: Whether consideration received for the assignment of registered trademarks constituted royalty or gains from the alienation of intellectual property rights under the India–Switzerland DTAA.
Background of the Dispute
During the financial year relevant to Assessment Year 2020–21, Novartis AG transferred specified Indian trademark rights relating to JALRA/JALRA-M, VYSOV/VYSOV-M and ZOMELIS/ZOMELIS-M to three Indian pharmaceutical companies: USV Limited, Cipla Limited and Eris Lifesciences Limited.
The aggregate consideration received from these transactions amounted to approximately ₹433.14 crore.
Novartis maintained that the transactions represented outright assignments of trademark ownership in India. Accordingly, it argued that the receipts were not taxable in India under Article 13(6) of the India–Switzerland Double Taxation Avoidance Agreement.
However, the Assessing Officer treated the entire consideration as royalty under Section 9(1)(vi) of the Income Tax Act, 1961, read with Article 12 of the DTAA. The Dispute Resolution Panel upheld the assessment, prompting Novartis to challenge the tax treatment before the Tribunal.
Revenue’s Arguments Against the Trademark Transfer
The Income Tax Department contended that the transactions did not constitute complete transfers of ownership. According to the Revenue, the purchasers were permitted to use the trademarks only within India and were restricted from exporting products bearing those marks.
The Department also relied on contractual restrictions concerning pharmaceutical products, trade dress and packaging. Further, Novartis retained rights over corresponding trademarks outside India.
On this basis, the Revenue argued that Novartis had effectively granted limited rights to use the trademarks rather than permanently transferring ownership. It therefore sought to tax the consideration as royalty.
ITAT Mumbai’s Analysis of Trademark Ownership
The Tribunal examined the assignment agreements and the nature of the rights transferred to the Indian purchasers. It found that the agreements conveyed ownership of the specified Indian trademark rights, along with the associated goodwill.
In the agreement involving USV Limited, the purchaser was expressly recognised as the absolute, sole and exclusive owner of the assigned trademarks in India. Novartis was also restricted from using those marks or asserting ownership over them within the territory covered by the assignment.
The Tribunal emphasised that a word mark can itself constitute transferable property. The fact that a trademark is registered as a word mark does not reduce ownership to a mere licence or permission to use it.
Referring to Sections 37, 38 and 45 of the Trade Marks Act, 1999, the Tribunal recognised that a registered proprietor may assign a trademark with or without goodwill and in respect of all or some of the goods or services for which it is registered. Registration of the assignee’s title further supports the transfer of ownership.
The Tribunal also clarified that a territorial restriction does not, by itself, invalidate an assignment. The transfer of Indian trademark rights does not require the seller to surrender its corresponding rights in other countries.
Similarly, the exclusion of existing packaging, trade dress or other corporate branding elements does not necessarily mean that ownership of the registered trademark has not been transferred. These elements are legally and commercially distinguishable from the trademark rights specifically assigned under the agreement.
Why the Consideration Was Not Treated as Royalty
Another significant factor considered by the Tribunal was the manner in which the consideration had been determined. The payment was fixed and was not linked to the purchasers’ future turnover, profits, productivity or the extent of their subsequent use of the trademarks.
The Tribunal found that the contractual restrictions were intended to define the territorial and product-related scope of the rights transferred. They did not establish that Novartis had retained ownership of the assigned Indian trademarks.
Distinguishing between the transfer of ownership and the right to use intellectual property, the Tribunal concluded that the receipts arose from the alienation of trademark rights rather than the grant of a continuing right to use those marks.
Application of the India–Switzerland DTAA
The Tribunal considered Article 12, which deals with royalties, and Article 13(6), concerning gains from the alienation of property, under the India–Switzerland DTAA.
It held that the consideration received by Novartis fell within Article 13(6) as gains arising from the alienation of the trademark rights. The Revenue had not established that the trademarks formed part of the business property of a permanent establishment of Novartis in India or that the gains fell within another relevant category under Article 13.
As Novartis was a tax resident of Switzerland, the Tribunal concluded that the gains were taxable only in Switzerland under the applicable treaty provision.
Consequently, the addition of ₹433.14 crore treated as royalty was deleted. The Tribunal left Novartis’s alternative argument concerning non-taxability under domestic law undecided because its ruling under the DTAA was sufficient to resolve the dispute.
Key Takeaways for Businesses and Tax Professionals
This decision offers several important lessons for companies undertaking trademark assignments and other cross-border intellectual property transactions:
- Trademark ownership can be transferred independently: An assignment of a registered trademark need not include every element of the seller’s corporate identity or branding.
- Territorial restrictions are not conclusive: Retaining trademark rights outside India does not automatically invalidate the transfer of ownership within India.
- Contractual drafting is crucial: Assignment agreements should clearly specify the rights transferred, territorial scope, associated goodwill, restrictions and ownership consequences.
- Royalty and capital gains require separate analysis: The tax treatment depends on the substantive rights transferred, the contractual arrangements and the applicable tax treaty.
- DTAA provisions can influence tax liability: Cross-border transactions must be examined under both domestic tax law and the relevant treaty, including the taxpayer’s eligibility for treaty benefits.
Conclusion
The ITAT Mumbai ruling in Novartis AG v. ACIT (International Taxation) reinforces the principle that an assignment of registered trademark rights should be evaluated on its actual legal and commercial substance. A transfer need not encompass the seller’s complete corporate identity, house marks or packaging to qualify as an assignment of ownership.
By deleting the ₹433.14 crore royalty addition, the Tribunal highlighted the distinction between transferring intellectual property ownership and merely granting the right to use it. The decision is particularly relevant to multinational enterprises, pharmaceutical companies, intellectual property owners and tax professionals handling cross-border trademark transactions.
Disclaimer: This article is intended for general information and professional discussion. The applicability of the ruling depends on the facts, contractual terms and relevant provisions of the applicable law and tax treaty.